The company believes its product, called Constellation, will differentiate itself from current commercial offerings in terms of throughput and multiplexing capability.
Investigators using droplet digital PCR methods are following cell-free tumor DNA in the blood, looking for patterns coinciding with immunotherapy treatment outcomes.
Researchers combined a microfluidic technology called the CTC-iChip with digital PCR to potentially improve cancer detection in hepatocellular carcinoma patients.
University of Cambridge researchers found that the portion of tumor DNA in patients' blood could predict treatment response and time to disease progression.
Esoterix sued Myriad in September, claiming that its myRisk Hereditary Cancer panel and services directly infringe four patents it has exclusively licensed.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
